Profile data is unavailable for this security.
About the company
Enlivex Ltd, formerly known as Enlivex Therapeutics Ltd, is an Israel-based clinical-stage macrophage reprogramming immunotherapy company developing Allocetra, an off-the-shelf cell therapy designed to restore macrophages to their homeostatic state. The Company focuses on diseases in which macrophages are pathologically reprogrammed, such as solid cancers, sepsis and COVID‑19, where non-homeostatic macrophages contribute significantly to disease severity. By re-establishing macrophage homeostasis, Allocetra has the potential to provide an immunotherapeutic mechanism of action for life-threatening indications defined as unmet medical needs, either as a stand‑alone therapy or in combination with other treatments.
- Revenue in USD (TTM)0.00
- Net income in USD-12.70m
- Incorporated2012
- Employees36.00
- LocationEnlivex Therapeutics Ltd14 Einstein St.NESS-ZIONA 7403618IsraelISR
- Phone+972 86623301
- Fax+972 86312981
- Websitehttps://www.enlivex.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Palisade Bio Inc | 0.00 | -11.23m | 259.27m | 8.00 | -- | 4.94 | -- | -- | -2.98 | -2.98 | 0.00 | 0.3522 | 0.00 | -- | -- | 0.00 | -137.67 | -130.84 | -221.20 | -165.85 | -- | -- | -- | -31,830.91 | -- | -1,041.55 | 0.0616 | -- | -100.00 | -- | -17.38 | -- | -- | -- |
| OmniAB Inc | 21.09m | -63.67m | 260.56m | 114.00 | -- | 0.9391 | -- | 12.35 | -0.5906 | -0.5906 | 0.1956 | 1.93 | 0.0658 | -- | 6.40 | 185,035.10 | -19.86 | -- | -20.75 | -- | 27.71 | -- | -301.83 | -101.09 | 4.96 | -- | 0.00 | -- | -22.75 | 7.58 | -22.55 | -- | 49.04 | -- |
| Silence Therapeutics plc | 25.81m | -65.01m | 273.01m | 115.00 | -- | 3.35 | -- | 10.58 | -0.462 | -0.462 | 0.1831 | 0.5227 | 0.1383 | -- | 124.98 | -- | -34.83 | -39.00 | -39.01 | -48.09 | 91.20 | 55.91 | -251.86 | -203.50 | -- | -- | 0.00 | -- | 36.71 | 168.26 | 16.45 | -- | 78.99 | -- |
| Enlivex Ltd | 0.00 | -12.70m | 284.86m | 36.00 | -- | 1.67 | -- | -- | -0.5454 | -0.5454 | 0.00 | 0.7196 | 0.00 | -- | -- | 0.00 | -50.07 | -38.63 | -56.56 | -42.99 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 48.35 | -- | -11.80 | -- |
| Minerva Neurosciences Inc | 0.00 | -14.03m | 295.56m | 8.00 | -- | -- | -- | -- | -1.85 | -1.85 | 0.00 | -4.94 | 0.00 | -- | -- | 0.00 | -39.57 | -35.73 | -44.01 | -37.64 | -- | -- | -- | -263.85 | -- | -- | 2.36 | -- | -- | -- | 104.80 | -- | -- | -- |
| TriSalus Life Sciences Inc | 40.21m | -72.25m | 299.06m | 110.00 | -- | -- | -- | 7.44 | -2.02 | -2.02 | 1.22 | -0.5357 | 1.26 | 1.76 | 8.11 | 365,518.20 | -123.81 | -- | -183.62 | -- | 84.04 | -- | -98.45 | -- | 2.75 | -6.61 | 5.43 | -- | 58.99 | -- | 47.75 | -- | -- | -- |
| Shattuck Labs Inc | 1.00m | -54.90m | 299.31m | 44.00 | -- | 3.20 | -- | 299.31 | -1.02 | -1.02 | 0.0178 | 1.48 | 0.0094 | -- | -- | 22,727.27 | -51.77 | -32.04 | -56.50 | -35.04 | -- | -- | -5,489.50 | -721.60 | -- | -- | 0.00 | -- | 245.26 | -10.36 | 13.62 | -- | -33.97 | -- |
| C4 Therapeutics Inc | 35.95m | -104.99m | 301.52m | 104.00 | -- | 1.17 | -- | 8.39 | -1.36 | -1.36 | 0.4337 | 2.65 | 0.1015 | -- | 13.06 | 345,644.20 | -29.63 | -27.16 | -33.31 | -30.47 | -- | -- | -292.08 | -328.00 | -- | -- | 0.00 | -- | 1.02 | 1.61 | 0.3058 | -- | -1.36 | -- |
| Amarin Corporation PLC | 213.65m | -38.80m | 302.49m | 80.00 | -- | 0.0329 | -- | 1.42 | -29.26 | -29.26 | 19.58 | 441.39 | 0.3151 | 0.5127 | 1.72 | 2,670,588.00 | -5.72 | -6.48 | -7.90 | -9.37 | 56.57 | 68.52 | -18.16 | -16.35 | 2.33 | -- | 0.00 | -- | -6.55 | -19.04 | 52.79 | -- | -- | -- |
| CytoDyn Inc | 0.00 | -40.35m | 307.44m | 13.00 | -- | -- | -- | -- | -0.0322 | -0.0322 | 0.00 | -0.0946 | 0.00 | -- | -- | 0.00 | -229.87 | -225.45 | -- | -- | -- | -- | -- | -184,742.10 | -- | -6.09 | -- | -- | -- | -- | 104.41 | -- | -- | -- |
| Aldeyra Therapeutics Inc | 0.00 | -33.85m | 312.65m | 8.00 | -- | 7.06 | -- | -- | -0.5637 | -0.5637 | 0.00 | 0.7355 | 0.00 | -- | -- | 0.00 | -38.32 | -33.16 | -51.97 | -37.60 | -- | -- | -- | -- | -- | -- | 0.2563 | -- | -- | -- | 39.40 | -- | -- | -- |
| Rezolute Inc | 0.00 | -84.23m | 313.89m | 71.00 | -- | 2.45 | -- | -- | -0.9239 | -0.9239 | 0.00 | 1.34 | 0.00 | -- | -- | 0.00 | -67.21 | -47.11 | -73.08 | -49.55 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -8.70 | -- | -- | -- |
| KALA BIO Inc | 0.00 | -35.84m | 314.68m | 38.00 | -- | -- | -- | -- | -5.94 | -5.94 | 0.00 | -1.17 | 0.00 | -- | -- | 0.00 | -90.62 | -61.19 | -316.35 | -75.37 | -- | -- | -- | -1,732.87 | -- | -12.71 | 1.44 | -- | -- | -- | 8.74 | -- | -31.05 | -- |
| Crescent Biopharma Inc | 0.00 | -55.96m | 316.63m | 4.00 | -- | 1.42 | -- | -- | -21.97 | -21.97 | 0.00 | 8.40 | 0.00 | -- | -- | 0.00 | -72.70 | -55.66 | -86.54 | -62.83 | -- | -- | -- | -2,068.09 | -- | -- | 0.00 | -- | -100.00 | -- | -2.66 | -- | -41.45 | -- |
Data as of Mar 04 2026. Currency figures normalised to Enlivex Therapeutics Ltd's reporting currency: US Dollar USD
